Moderna mRNA supplier, Lonza, let's CEO go on concerns over earnings prospects
Let battle commence between the legal teams—who will pick up the tab for obsolescence?
Pfizer’s trusty ‘fact checker’, Reuters, has just reported some incredibly significant news:
“Contract drug manufacturer Lonza (LONN.S) said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about the group's medium-term profit prospects.
Keep reading with a 7-day free trial
Subscribe to INSIDE PHARMA to keep reading this post and get 7 days of free access to the full post archives.